Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 14 May 2019, 09:12 HKT/SGT
Share:
    

Source: NEC Corporation
NEC Becomes the First Japanese Company to Join the TESLA Consortium's Fight Against Cancer

TOKYO, May 14, 2019 - (JCN Newswire) - NEC Corporation (TSE: 6701) has become the first Japanese company to join the Tumor neoantigEn SeLection Alliance (TESLA) founded and managed by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI). This global bioinformatics collaborative includes scientists from more than 35 of the leading neoantigen research groups in academia, nonprofit and industry. The goal is to find the best algorithms to predict which cancer neoantigens encoded in DNA and RNA can be recognized by and stimulate an immune response.

Individualized neoantigen vaccines, which are tailored to each patient's tumor, are one of most advanced cancer treatments to show great promise for activating the immune system to fight cancer whilst reducing the chances of autoimmune responses.

NEC was accepted into the TESLA consortium given the uniqueness of the company's Neoantigen Prediction System. The prediction system utilizes NEC's cutting-edge AI technology, "NEC the WISE"(1), to identify and prioritize patient-specific neoantigens. NEC comprehensively evaluates candidate neoantigens with a primary focus placed on its in-house MHC-binding affinity prediction. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.

"By participating in this consortium, NEC will be able to collaborate with the world's leading research organizations and potentially improve the chances of survival for cancer patients with this new treatment option," said Osamu Fujikawa, Senior Vice President, NEC Corporation. "NEC focuses on the provision of social solutions and continues efforts to strengthen its next-generation healthtech businesses," he added.

(1) NEC the WISE
NEC the WISE is a term for the Company's cutting-edge portfolio of AI technologies.


Contact:
NEC
Seiichiro Toda        
s-toda@cj.jp.nec.com
+81-3-3798-6511


Topic: Press release summary
Source: NEC Corporation

Sectors: Cloud & Enterprise, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


NEC Corporation Links

http://www.nec.com

https://www.facebook.com/nec.global/

https://twitter.com/NEC_corp

https://www.youtube.com/user/NECglobalOfficial

https://www.linkedin.com/company/nec/

NEC Corporation
Apr 9, 2025 10:09 HKT/SGT
NEC Face Recognition Ranks First in NIST Accuracy Testing
Apr 8, 2025 15:42 HKT/SGT
NEC Orchestrating Future Fund invests in Rescale, Inc., provider of a leading digital engineering platform for cloud high-performance computing (HPC)
Apr 8, 2025 15:11 HKT/SGT
SITA and NEC Collaborate to Drive Global Adoption of Digital Identities in Travel
Apr 1, 2025 15:15 HKT/SGT
NEC has developed technologies that enable a secure workflow for personalized cancer vaccines and has proven their capabilities
Mar 28, 2025 12:08 HKT/SGT
NEC and COEDO Brewery develop the second edition of "The taste of life created by brewers and AI -- Agentic AI x Craft Beer"
Mar 26, 2025 13:41 HKT/SGT
NEC provides 25G tunable SFP extended reach optical transceiver
Mar 25, 2025 16:14 HKT/SGT
NEC receives order for walkthrough gates leveraging face recognition technology to facilitate more seamless airport arrival and departure procedures
Mar 25, 2025 15:40 HKT/SGT
NTT, DOCOMO and NEC Demonstrate World's Fastest 140 Gbps Bidirectional Wireless Transmission in 80 GHz Band
Mar 10, 2025 11:10 HKT/SGT
CEPI funds Nagasaki University to develop innovative vaccines using Nanoball platform and NEC's AI
Mar 6, 2025 12:20 HKT/SGT
NEC improves the energy efficiency and floor space density of 5G Mobile Core systems
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: